Venetoclax Plus Hypomethylating Agent for 7‐ Versus 14‐ Versus 21‐ Versus 28‐Day Cycles in Newly‐Diagnosed Acute Myeloid Leukemia:
ELN
and Mayo Genetic Risk–Stratified Analysis in 540 Patients
Study limitation reported by the research below: “The study does not report rates of remission (CR/CRi) or MRD negativity by venetoclax duration, which are key intermediate endpoints in AML.”